KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Health Sciences and Medicine / 2026 / Volume: 8 Issue: 3

Akromegali hastalarında yükselmiş monosit ve yüksek yoğunluklu lipoprotein kolesterol oranının endotel disfonksiyonu ve kardiyovasküler risk üzerindeki rolü

The role of elevated monocyte and high-density lipoprotein cholesterol ratio in endothelial dysfunction and cardiovascular risk in acromegaly patients

Mustafa Aydemir(AKDENIZ UNIVERSITY)0000-0002-5145-0920
Ramazan Sarı(AKDENIZ UNIVERSITY, FACULTY OF MEDICINE)0000-0002-6989-1492
Sayfa
—
Yayın Tarihi
2025-05-30
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgular: Akromegali hastalarında ortalama MHR, sağlıklı kontrol grubuna kıyasla istatistiksel olarak anlamlı derecede yüksek bulunmuştur.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Amaç: Bu çalışma, akromegali hastalarında monosit/yüksek dansiteli lipoprotein oranının (MHR) endotel disfonksiyonu ve kardiyovasküler risk üzerindeki rolünü incelemeyi amaçlamıştır.
📊
Temel Bulgular & Veri:Yöntem: Çalışma grubu, akromegali tanısı almış 125 hastadan, kontrol grubu ise hipofizer insidentoloma nedeniyle endokrin kliniğine başvuran ancak akromegali tanısı olmayan 123 sağlıklı bireyden oluşmuştur.
💡
Sonuç & Katkı:Bulgular: Akromegali hastalarında ortalama MHR, sağlıklı kontrol grubuna kıyasla istatistiksel olarak anlamlı derecede yüksek bulunmuştur.
🔬Tür:Laboratuvar & Saha Deneyi
📍Kapsam:125 hasta
⚙️Değişkenler:Acromegaly · monocyte to HDL cholesterol ratio · cardiovascular risk

Özet

Amaç: Bu çalışma, akromegali hastalarında monosit/yüksek dansiteli lipoprotein oranının (MHR) endotel disfonksiyonu ve kardiyovasküler risk üzerindeki rolünü incelemeyi amaçlamıştır. Yöntem: Çalışma grubu, akromegali tanısı almış 125 hastadan, kontrol grubu ise hipofizer insidentoloma nedeniyle endokrin kliniğine başvuran ancak akromegali tanısı olmayan 123 sağlıklı bireyden oluşmuştur. Tüm katılımcıların medikal ve laboratuvar kayıtları retrospektif olarak incelenmiştir. Bulgular: Akromegali hastalarında ortalama MHR, sağlıklı kontrol grubuna kıyasla istatistiksel olarak anlamlı derecede yüksek bulunmuştur. Akromegali grubunda, sistolik kan basıncı, glikoz, HbA1c, lipitler (toplam kolesterol, LDL, trigliseritler), sedimentasyon hızı, CRP ve nötrofiller kontrol grubuna kıyasla anlamlı olarak daha yüksekti. Akromegali için optimal MHR cutoff değeri 12.01 olup, %85,1 sensitivity, %85 specificity ve 0.64 AUC değerine sahipti. Sonuç: Enflamasyonun bir göstergesi olarak kabul edilen potansiyel bir biyobelirteç olan MHR, akromegali hastalarında sağlıklı gruba kıyasla anlamlı derecede yüksek bulunmuştur. Bu durum, MHR'nin akromegali hastalarında kardiyovasküler risk ve endotel disfonksiyonunu değerlendirmede yararlı bir gösterge olabileceğini düşündürmektedir.

Abstract

Aims: This study aimed to investigate the role of the monocyte-to-high-density lipoprotein ratio (MHR) as an indicator of endothelial dysfunction and cardiovascular risk in patients with acromegaly. Methods: The study group consisted of 125 patients diagnosed with acromegaly, while the control group included 123 healthy individuals who visited the endocrine clinic due to pituitary incidentaloma but had no acromegaly diagnosis. Medical and laboratory records of all participants were reviewed retrospectively. Results: The average MHR in patients with acromegaly was found to be statistically significantly higher than that in the healthy control group. In the acromegaly group, systolic blood pressure, glucose, HbA1c, lipids (total cholesterol, LDL, triglycerides), sedimentation rate, CRP, and neutrophils were significantly higher to the control group. The optimal MHR cutoff for acromegaly was 12.01, with 85.1% sensitivity, 85% specificity, and an AUC of 0.64. Conclusion: MHR, a potential biomarker considered an indicator of inflammation, was significantly higher in patients with acromegaly compared to the healthy control group. This finding suggests that MHR may serve as a useful marker for assessing cardiovascular risk and endothelial dysfunction in patients with acromegaly.

🔖

Bu Makaleye Atıf Yap

Aydemir, M., Sarı, R. (2025). Akromegali hastalarında yükselmiş monosit ve yüksek yoğunluklu lipoprotein kolesterol oranının endotel disfonksiyonu ve kardiyovasküler risk üzerindeki rolü. Journal of Health Sciences and Medicine, Volume: 8 Issue: 3. https://doi.org/10.32322/jhsm.1668960

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (37)

  1. Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome. Biochem Pharmacol. 2015;93(4):409-417. doi: 10.1016/j.bcp.2014.12.006
  2. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol. 2008;69(3):347-358. doi:10.1111/j.1365-2265. 2008.03292.x
  3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic compli- cations of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. doi:10.1210/er. 2002-0022
  4. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013; 16(3):294-302. doi:10.1007/s11102-012-0420-x
  5. Wolters TLC, Netea MG, Riksen NP, Hermus ARMM, Netea-Maier RT. Acromegaly, inflammation and cardiovascular disease: a review. Rev Endocr Metab Disord. 2020;21(4):547-568. doi:10.1007/s11154-020-09560-x
  6. Villanueva DLE, Tiongson MD, Ramos JD, Llanes EJ. Monocyte to high-density lipoprotein ratio (MHR) as a predictor of mortality and major adverse cardiovascular events (MACE) among ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention: a meta-analysis. Lipids Health Dis. 2020;19(1):55. doi:10.1186/s12944-020-01242-6
  7. Ridker PM, Everett BM, Thuren T, et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12): 1119-1131. doi:10.1056/NEJMoa1707914
  8. Higashi Y, Quevedo HC, Tiwari S, et al. Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging. Front Horm Res. 2014;43:107-124. doi:10.1159/000360571
  9. Maffei P, Dassie F, Wennberg A, Parolin M, Vettor R. The endothelium in acromegaly. Front Endocrinol (Lausanne). 2019;10:437. doi:10.3389/fendo.2019.00437
  10. Hong FF, Liang XY, Liu W, et al. Roles of eNOS in atherosclerosis treatment. Inflamm Res. 2019;68(6):429-441. doi:10.1007/s00011-019-01229-9
  11. Caicedo D, Díaz O, Devesa P, Devesa J. Growth hormone (GH) and cardiovascular system. Int J Mol Sci. 2018;19(1):290. doi:10.3390/ijms 19010290
  12. Groh L, Keating ST, Joosten LAB, Netea MG, Riksen NP. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol. 2018;40(2):203-214. doi:10.1007/s00281-017-0656-7
  13. Choi SH, Kim JH, Lim S, et al. Monocyte count as a predictor of cardiovascular mortality in older Korean people. Age Ageing. 2017;46(3): 433-438. doi:10.1093/ageing/afw226
  14. Açıkgöz SK, Açıkgöz E, Şensoy B, Topal S, Aydoğdu S. Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction. Cardiol J. 2016;23(5):505-512. doi:10.5603/CJ.a2016.0026
  15. Cetin MS, Ozcan Cetin EH, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ. 2016;25(11):1077-1086. doi:10.1016/j.hlc.2016.02.023
  16. Karatas A, Turkmen E, Erdem E, Dugeroglu H, Kaya Y. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomark Med. 2018;12(9):953-959. doi:10.2217/bmm-2018-0048
  17. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468-1474. doi:10.1016/0735-1097(94)90141-4
  18. Paulus WJ. Unfolding discoveries in heart failure. N Engl J Med. 2020; 382(7):679-682. doi:10.1056/NEJMcibr1913825
  19. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press. 2005;14(4):227-232. doi:10.1080/08037050510034293
  20. Soeki T, Sata M. Inflammatory biomarkers and atherosclerosis. Int Heart J. 2016;57(2):134-139. doi:10.1536/ihj.15-346
  21. Ridker PM. From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
  22. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709-721. doi:10.1038/nri3520
  23. Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC. Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vasc Health Risk Manag. 2015;11:173-183. doi:10.2147/ VHRM.S68415
  24. Brown RA, Shantsila E, Varma C, Lip GY. Current understanding of atherogenesis. Am J Med. 2017;130(3):268-282. doi:10.1016/j.amjmed.2016.10.022
  25. Boero L, Manavela M, Gomez Rosso L, et al. Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol. 2009;70(1):88-95. doi:10.1111/j.1365-2265.2008.03323.x
  26. Boero L, Manavela M, Merono T, Maidana P, Gomez Rosso L, Brites F. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol. 2012;77(4):579-585. doi:10.1111/j.1365-2265.2012.04414.x
  27. Ueland T, Fougner SL, Godang K, et al. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. J Clin Endocrinol Metab. 2010;95(1):361-368. doi:10.1210/jc.2009-0422
  28. Sodhi A, Tripathi A. Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophages in vitro: involvement of p-38 MAP kinase, STAT3 and NF-kappaB. Cytokine. 2008;41(2):162-173. doi:10. 1016/j.cyto.2007.11.007
  29. CDC, Adult BMI calculator 2020. https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/bmi_calculator.html (Accessed 21/04/2021 2021).
  30. Meidert AS, Saugel B. Techniques for non-invasive monitoring of arterial blood pressure. Front Med (Lausanne). 2018;4:231. doi:10.3389/fmed.2017.00231
  31. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579
  32. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11): 3933-3951. doi:10.1210/jc.2014-2700
  33. Ganjali S, Gotto AM Jr, Ruscica M, et al. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol. 2018;233(12):9237-9246. doi:10.1002/jcp.27028
  34. Selcuk M, Yildirim E, Saylik F. Comparison of monocyte with high density lipoprotein cholesterol ratio in dipper and nondipper hypertensive patients. Biomark Med. 2019;13(15):1289-1296. doi:10.2217/ bmm-2019-0062
  35. Kaplan IG, Kaplan M, Abacioglu OO, Yavuz F, Saler T. Monocyte/HDL ratio predicts hypertensive complications. Bratisl Lek Listy. 2020;121(2): 133-136. doi:10.4149/BLL_2020_018
  36. Gökçay Canpolat A, Emral R, Keskin Ç, Canlar Ş, Şahin M, Çorapçioğlu D. Association of monocyte-to-high density lipoprotein-cholesterol ratio with peripheral neuropathy in patients with type II diabetes mellitus. Biomark Med. 2019;13(11):907-915. doi:10.2217/bmm-2018-0451
  37. Onalan E. The relationship between monocyte to high-density lipoprotein cholesterol ratio and diabetic nephropathy. Pak J Med Sci. 2019;35(4): 1081-1086. doi:10.12669/pjms.35.4.534